Navigation Links
Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
Date:6/21/2012

SAN MATEO, Calif., June 21, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it appointed Darlene Horton, M.D. as its Chief Medical Officer.

Dr. Horton was previously Chief Medical Officer of Itero Biopharmaceuticals, a venture-backed company that developed and out-licensed a biosimilar protein therapeutic. Previous to Itero, Dr. Horton served as Senior Vice President, Clinical Research at Scios, Inc., a Johnson & Johnson (J&J) company. During her 12 year tenure at Scios, she was the clinical lead for Natrecor®, a commercial product indicated for the treatment of acute heart failure. Dr. Horton led the program from late-stage development through approval and commercialization. She presented the program to the FDA's Cardiovascular and Renal Advisory Committee prior to successful approval. Following the acquisition of Scios by J&J, Dr. Horton also served as the Head of the Cardiovascular Therapeutic Area Center of Excellence for all of J&J pharmaceutical companies.

"We are excited for Dr. Horton to join the Nile team," said Joshua Kazam, Chief Executive Officer of Nile. "We believe Dr. Horton's proven track record in the development of cardiovascular therapies will be invaluable to Nile as we push forward the cenderitide post-acute heart failure program."

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Stat
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
2. Lonza and BioWa Sign License Agreements with FivePrime Therapeutics for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
3. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
4. Novelos Therapeutics Prices $5.4 Million Public Offering
5. Sorrento Therapeutics Awarded Third Phase I STTR Grant
6. ICU Medicals ChemoClave™ System Included in Mobius Therapeutics Mitosol® Kit for Use in Glaucoma Surgery
7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
8. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
(Date:7/28/2015)... A German Diabetes Center clinical study found ... probiotic enriches human gut microbiota and modifies gut production ... involved daily administration of Nutraceutix,s L. reuteri ... BIO- tract ® delivery technology that protects ... way to the intestinal tract. The randomized, ...
(Date:7/28/2015)... Research and Markets ... the "Craniomaxillofacial Implants Market - Global Industry ... - 2022" report to their offering. ... studies the current and future prospects of the ... in the global market due to increasing facial ...
Breaking Medicine Technology:Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2
... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...
... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...
Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5
(Date:7/28/2015)... ... July 28, 2015 , ... Darryl Worley’s ... volunteers celebrate the 14th year of raising money for the Darryl Worley Foundation. ... for this year’s main concert Saturday, Oct. 3. , This year’s concert will ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Denver ... of Philanthropy Reframed and Exhibited,” a photographic and narrative exploration of African American ... historic Five Points neighborhood. , Denver is one of only ten cities to ...
(Date:7/28/2015)... ... July 28, 2015 , ... By 2016, the number of ... to engage with customers on a highly personal basis, increasing customer loyalty. However, capitalizing ... big growth opportunities or lose customers to more nimble competitors. , The Open Mobile ...
(Date:7/28/2015)... ... 2015 , ... Morristown Medical Center, part of Atlantic Health System, today announced ... hospitals in the nation, to implant the newly approved CoreValve® Evolut® R System from ... in good condition. , The CoreValve® Evolut® R System was approved by the U.S. ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Edward ... arrival of Dr. Sudeep Roy in July 2016. Coming to Austin from Philadelphia, ... Dr. Buckingham. The twelve-month long training is facilitated annually by the American Academy ...
Breaking Medicine News(10 mins):Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 2Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 3Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... was announced that the,U.S. Court of Federal Claims ... favor of a child who regressed into autism ... the mercury-based preservative,thimerosal., Case documents state that ... underlying condition that ultimately led to,regressive encephalopathy and ...
... the University of Minnesota and North Carolina State University ... friendship and companionship they also share the same ... the researchers say that because of the way the ... some humans and dogs. , Jaime Modiano, V.M.D., Ph.D., ...
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Blue Cross and Blue,Shield,s Member Health Index has ... of the Blue Cross and Blue Shield Association, ... Shield companies are,working to increase the efficiency and ... Department of Health Care Policy,evaluates submissions from participating ...
... the full line of dermatologist endorsed moisturizers, ... the,makers of a full line of dermatologist endorsed ... skin conditions, is launching its 2008,"Prepare to Unveil ... looking and beautiful skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, ...
Cached Medicine News:Health News:Population Health Impact Institute Announces New Board Members 2Health News:Government Concludes Vaccines Caused Autism 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4
... critical patients more waveforms, 12-Lead ECG, ... package and cardiac output bundled into ... with your patients., We use quick-action ... which means less time spent looking,through ...
... comfort. The Nylon Finger Trap are gentle on ... Nylon Finger Traps create a complete upper extremity ... Digi Grip or ISI Advanced Universal K Table. ... packs and come in five sizes: Extra-small, small, ...
... FH system uses a ... infrastructure operating in ... communication of patient information. ... of up to 640 ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
Medicine Products: